CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Enzalutamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02384382
NCT02384382Phase 2Completed
CompareCT.gov

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Pfizer·interventional·Posted Mar 10, 2015·Updated May 5, 2020

In Brief

A Phase 2 clinical trial evaluating Enzalutamide for Prostate Carcinoma Metastatic to the Bone and Castration Resistant Prostate Cancer. Completed, enrolled 23 participants across 5 sites.

Detailed Summary

The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who are receiving enzalutamide for castration-resistant prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
CountriesUnited States
CollaboratorsAstellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 10, 2015
Enrollment StartNov 30, 2015
Primary CompletionMay 3, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.3 years ago

Interventions

Enzalutamidedrug